Cargando…

Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer

IMPORTANCE: The neoadjuvant treatment options for ERBB2-positive (also known as HER2-positive) breast cancer are associated with different rates of pathologic complete response (pCR). The KATHERINE trial showed that adjuvant trastuzumab emtansine (T-DM1) can reduce recurrence in patients with residu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunst, Natalia, Wang, Shi-Yi, Hood, Annette, Mougalian, Sarah S., DiGiovanna, Michael P., Adelson, Kerin, Pusztai, Lajos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684449/ https://www.ncbi.nlm.nih.gov/pubmed/33226431 http://dx.doi.org/10.1001/jamanetworkopen.2020.27074

Ejemplares similares

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
por: Rozenblit, Mariya, et al.
Publicado: (2021)

Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
por: Jaber Chehayeb, Rachel, et al.
Publicado: (2022)

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
por: Lin, Nancy U., et al.
Publicado: (2022)

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
por: Sanft, Tara, et al.
Publicado: (2015)

Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?: Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
por: Krawczyk, Natalia, et al.
Publicado: (2022)

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
por: Press, Michael F., et al.
Publicado: (2018)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer
por: Braman, Nathaniel, et al.
Publicado: (2019)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer()
por: Harbeck, Nadia
Publicado: (2022)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2− locally advanced breast cancer
por: Petry, V., et al.
Publicado: (2015)

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial
por: Pivot, Xavier, et al.
Publicado: (2022)

The Mysterious Ways of ErbB2/HER2 Trafficking
por: Bertelsen, Vibeke, et al.
Publicado: (2014)

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
por: Cortés, Javier, et al.
Publicado: (2020)

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer
por: Toomey, Sinead, et al.
Publicado: (2016)

Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors
por: Marotta, Michael, et al.
Publicado: (2017)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
por: Fernandez-Martinez, Aranzazu, et al.
Publicado: (2023)

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
por: Li, Junjie, et al.
Publicado: (2018)

Prognostic value of ErbB2/HER2 in human meningiomas
por: Arnli, Magnus B., et al.
Publicado: (2018)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
por: Landgraf, Ralf
Publicado: (2007)

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy
por: Gonzalez-Angulo, A M, et al.
Publicado: (2015)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
por: Toomey, Sinead, et al.
Publicado: (2017)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab
por: Wang, Shuo, et al.
Publicado: (2022)

Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns
por: Gougis, Paul, et al.
Publicado: (2023)

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis
por: Debiasi, Márcio, et al.
Publicado: (2018)

Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research
por: Cardillo, Anthony B., et al.
Publicado: (2023)

Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools
por: Patel, Jaymin M., et al.
Publicado: (2016)

Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence
por: Ongaratti, B.R., et al.
Publicado: (2016)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
por: Rediti, Mattia, et al.
Publicado: (2023)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
por: Sevcikova, Katarina, et al.
Publicado: (2013)

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q6knhvodabntcogj7paoe4gacu